FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* WORLAND STEPHEN T						2. Issuer Name <b>and</b> Ticker or Trading Symbol  Tracon Pharmaceuticals, Inc. [ TCON ]								Relationship of Reporting Person(s) to Issuer heck all applicable)  X Director 10% Owner					
(Last) (First) (Middle) 4350 LA JOLLA VILLAGE DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 06/15/2017									Office below	(give title		Other (s <sub>l</sub> below)	pecify	
SUITE 800						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) SAN DIEGO CA 92122			92122											X Form filed by One Reporting Person  Form filed by More than One Reporting  Person					
(City)	(S	tate)	(Zip)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Executio			Date,	Code (Ins	Transaction Disposed Code (Instr. 5)		ties Acquired (A) o d Of (D) (Instr. 3, 4 a		Benefic Owned	s For ally (D) ollowing (I) (		: Direct c r Indirect E str. 4) C	7. Nature of Indirect Beneficial Ownership	
									Code V	An	mount	(A) or (D)	Price	Reporte Transac (Instr. 3	ion(s)			Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/\)	Co	ansaci ode (In		of		6. Date Exercisable Expiration Date (Month/Day/Year)		and	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Co	ode \	v	(A)	(D)	Date Exercisable	Expir Date	ration	Title	Amount or Number of Shares						
Director Stock Option (Right to Buy)	\$2.15	06/15/2017			A		15,000		(1)	06/14	1/2027	Common Stock	15,000	\$0.00	15,000	0	D		

## **Explanation of Responses:**

1. The shares subject to the option shall vest and become exercisable on the earlier of the first anniversary of the grant date set forth in column 3 above or the date of the next annual meeting of the Company's stockholders.

## Remarks:

/s/ Patricia L. Bitar, Attorney-In-Fact

06/15/2017

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.